A5008104669- Epigenetics and DNA Methylation
- Pancreatic and Hepatic Oncology Research
- Cancer, Hypoxia, and Metabolism
- Protein Hydrolysis and Bioactive Peptides
- Sphingolipid Metabolism and Signaling
- Caveolin-1 and cellular processes
- Immunotherapy and Immune Responses
- Cancer, Lipids, and Metabolism
- Drug Transport and Resistance Mechanisms
- Cancer Immunotherapy and Biomarkers
- Phagocytosis and Immune Regulation
- Polyamine Metabolism and Applications
The University of Texas MD Anderson Cancer Center
2020-2021
Georgetown University
2019
Abstract Plasma and tumor caveolin-1 (Cav-1) are linked with disease progression in prostate cancer. Here we report that metabolomic profiling of longitudinal plasmas from a prospective cohort 491 active surveillance (AS) participants indicates prominent elevations plasma sphingolipids AS progressors that, together Cav-1, yield prognostic signature for progression. Mechanistic studies the underlying supportive onco-metabolism reveal coordinated activities through which Cav-1 enables rewiring...
Abstract Background MYC is an oncogenic driver of development and progression in triple-negative breast cancer (TNBC). Ornithine decarboxylase, the rate-limiting enzyme polyamine metabolism, a transcriptional target MYC. We therefore hypothesized that plasma signature may be predictive TNBC progression. Methods Using liquid chromatography mass spectrometry, levels were determined samples from newly diagnosed patients with (n = 87) cancer-free controls 115). Findings validated independent...
Intra-tumoral expression of the serine hydrolase carboxylesterase 2 (CES2) contributes to activation pro-drug irinotecan in pancreatic ductal adenocarcinoma (PDAC). Given other potential roles CES2, we assessed its regulation, downstream effects, and contribution tumor development PDAC. Association between mRNA CES2 tumors overall survival was using The Cancer Genome Atlas. Cell viability, clonogenic, anchorage-independent growth assays as well an orthotopic mouse model PDAC were used...
PURPOSE The combination chemotherapy of fluorouracil, leucovorin, irinotecan, and oxaliplatin (FOLFIRINOX) has provided clinically meaningful improvement for pancreatic ductal adenocarcinoma (PDAC). We previously uncovered a role the serine hydrolase carboxylesterase 2 (CES2) in mediating intratumoral activation prodrug constituent FOLFIRINOX. aimed to further test predictive value CES2 response irinotecan using patient-derived xenograft (PDX) models elucidate determinants expression...